<DOC>
	<DOCNO>NCT02140736</DOCNO>
	<brief_summary>The main aim study observe correction hemoglobin level patient chemotherapy , treat epoetin alfa biosimilar presenting solid tumor lymphoma myeloma .</brief_summary>
	<brief_title>Epoetin Alfa Biosimilar Management Chemotherapy-Induced Symptomatic Anemia Haematology Oncology</brief_title>
	<detailed_description>This non-interventional , descriptive , national , multi-site , longitudinal prospective observational study adult patient suffer cancer malignant blood disease whose chemotherapy treatment induce symptomatic anemia treat biosimilar epoetin correct haemoglobin level .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Patients 18 year age Patients present anemia follow chemotherapy Patients suffer solid tumour , malignant hemopathies , lymphoma myeloma present anemia follow chemotherapy The patient may include regardless chemotherapy cycle ( first cycle last cycle ) Patients eligible epoetin alfa biosimilar treatment Patients receive chemotherapy Patients already include epoetin zeta trial Patients present contraindication epoetin zeta Patients present hypersensitivity active principle excipients Patient erythroblastopenia acquire pure red cell aplasia ( APRCA ) Patient uncontrollable arterial hypertension Patients receive adequate prophylaxis antithrombotic agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Chemotherapy-induced anemia</keyword>
	<keyword>Epoetin biosimilar</keyword>
</DOC>